Endologix to Present at Three Upcoming Investor Conferences
November 21 2011 - 9:00AM
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative
treatments for aortic disorders, announced today that John
McDermott, President and Chief Executive Officer, is scheduled to
present at two upcoming investor conferences and Bob Krist, Chief
Financial Officer, is scheduled to present at one upcoming
conference. The first presentation will be at the 23rd Annual Piper
Jaffray Health Care Conference in New York City.
Event: 23rd Annual Piper Jaffray Health Care
Conference
Date: Wednesday, November 30, 2011
Time: 9:30 a.m. ET / 6:30 a.m. PT
Endologix Participant: John McDermott,
President and Chief Executive Officer
The second presentation will be at the 6th Annual Canaccord
Genuity Cardiovascular, Diabetes & Obesity Conference in San
Francisco.
Event: 6th Annual Canaccord Genuity
Cardiovascular, Diabetes & Obesity Conference
Date: Tuesday, December 6, 2011
Time: 5:00 p.m. ET / 2:00 p.m. PT
Endologix Participant: Bob Krist, Chief
Financial Officer
The Third presentation will be at the Oppenheimer 22nd Annual
Healthcare Conference in New York City.
Event: Oppenheimer 22nd Annual Healthcare
Conference
Date: Tuesday, December 13, 2011
Time: 9:40 a.m. ET / 6:40 a.m. PT
Endologix Participant: John McDermott,
President and Chief Executive Officer
An audio webcast of the Company's presentations will be
available by visiting the investor relations section of Endologix's
website at www.endologix.com. A replay of the presentations
will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. (the "Company") develops and manufactures
minimally invasive treatments for aortic disorders. The Company's
focus is endovascular stent grafts for the treatment of abdominal
aortic aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix's Web site at
www.endologix.com.
CONTACT: COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
(949) 595-7200
www.endologix.com
INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2024 to May 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From May 2023 to May 2024